Sleep Medicine
Volume 10, Issue 4 , Pages 416-421 , April 2009

Exacerbation of cataplexy following gradual withdrawal of antidepressants: Manifestation of probable protracted rebound cataplexy

  • Ruzica K. Ristanovic

      Affiliations

    • Sleep Disorders Center, Department of Neurology, ENH-Evanston Hospital, 2650 Ridge Avenue, Evanston, IL 60201, United States
    • Corresponding Author InformationCorresponding author. Tel.: +1 847 663 8202; fax: +1 847 663 8211.
    • ,
  • Howard Liang

      Affiliations

    • Eagle Creek Research Solutions, 12468 Independence Avenue, Savage, MN 55378, United States
    • ,
  • Carl S. Hornfeldt

      Affiliations

    • Consultant to Jazz Pharmaceuticals, Inc., 1000 Westgate Drive, Suite 242, St. Paul, MN 55114, United States
    • ,
  • Chinglin Lai

      Affiliations

    • Jazz Pharmaceuticals, Inc., 3180 Porter Drive, Palo Alto, CA 94304, United States

Received 23 February 2007 ,Revised 13 March 2008 ,Accepted 23 April 2008.

References 

  1. Akimoto H, Honda Y, Takahashi Y. Pharmacotherapy in narcolepsy. Dis Nerv Syst. 1960;21:704–706
  2. Houghton WC, Scammell TE, Thorpy M. Pharmacotherapy for cataplexy. Sleep Med Rev. 2004;8:355–366
  3. Scammell TE. The neurobiology, diagnosis and treatment of narcolepsy. Ann Neurol. 2003;53:154–166
  4. Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol. 1997;52:27–78
  5. Chen CN. The use of clomipramine as an REM sleep suppressant in narcolepsy. Postgrad Med J. 1980;56(Suppl. 1):86–89
  6. Wing YK, Lee S, Chiu HF, Ho CK, Chen CN. A patient with coexisting narcolepsy and morbid jealousy showing favourable response to fluoxetine. Postgrad Med J. 1994;70:34–36
  7. Smith M, Parkes JD, Dahlitz M. Venlafaxine in the treatment of the narcoleptic syndrome. J Sleep Res. 1996;5(Suppl. 1):217
  8. Guilleminault C, Mancuso J, Salva MA, et al. Viloxazine hydrochloride in narcolepsy: a preliminary report. Sleep. 1986;9(1 Pt. 2):275–279
  9. Larrosa O, de la Llave Y, Bario S, Granizo JJ, Garcia-Borreguero D. Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study. Sleep. 2001;24:282–285
  10. Kratochvil CJ, Vaughan BS, Harrington MJ, Burke WJ. Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Pharmacother. 2003;4:1165–1174
  11. Guilleminault C, Raynal D, Takahashi S, Carskadon M, Dement W. Evaluation of short-term and long-term treatment of the narcolepsy syndrome with clomipramine hydrochloride. Acta Neurol Scand. 1976;54:71–87
  12. Martinez-Rodriguez J, Iranzo ASJ, Genis D, Molins A, Silva Y, Melendez R. Status cataplecticus induced by abrupt withdrawal of clomipramine. Neurologia. 2002;17:113–116
  13. Parkes JD, Schachter M. Clomipramine and clonazepam in cataplexy. Lancet. 1979;2:1085–1086
  14. Schachter M, Parkes JD. Fluvoxamine and clomipramine in the treatment of cataplexy. J Neurol Neurosurg Psychiatry. 1980;43:171–174
  15. Langdon N, Shindler J, Parkes JD, Bandak S. Fluoxetine in the treatment of cataplexy. Sleep. 1986;9:371–373
  16. Scharf MB, Fletcher K. Rebound cataplexy, a complication of drug withdrawal in narcolepsy. Sleep Res. 1988;17:246
  17. Poryazova R, Siccoli M, Werth E, Bassetti CL. Unusually prolonged rebound cataplexy after withdrawal of fluoxetine. Neurology. 2005;65:967–968
  18. Ristanovic RK. Severity of rebound cataplexy is worse following the discontinuation of tricylic antidepressants (TCAs) than selective serotonin reuptake inhibitors (SSRIs). Sleep. 2006;29(Suppl.):A219–A220
  19. Xyrem® International Study Group. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Med 2005;6:415–21.
  20. Xyrem® International Study Group. A double-blind, placebo-controlled, study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med 2005;1:289–95.
  21. American Academy of Sleep Medicine. International classification of sleep disorders, revised: diagnostic and coding manual. Chicago, IL: American Academy of Sleep Medicine; 2001.
  22. Gelb M, Guilleminault C, Kraemer H, et al. Stability of cataplexy over several months-information for the design of therapeutic trials. Sleep. 1994;17:265–273
  23. Hublin C. Narcolepsy. Current drug treatment options. CNS Drugs. 1996;5:426–436
  24. Vignatelli L, D’Alessandro R, Candelise L. Antidepressant drugs for narcolepsy. Cochrane Database Syst Rev. 2005;3:CD003724
  25. US Xyrem® Multicenter Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002;25:42–9.
  26. US Xyrem® Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 2004;5:119–23.
  27. US Xyrem® Multicenter Study Group. The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms. J Toxicol Clin Toxicol 2003;41:131–5.

PII: S1389-9457(08)00115-9

doi: 10.1016/j.sleep.2008.04.004

Sleep Medicine
Volume 10, Issue 4 , Pages 416-421 , April 2009

Article Tools

* Image Usage & Resolution